Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Monopar Therapeutics Inc. (MNPR : NSDQ)

• Company Description    Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United States. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $43.73 Daily Weekly Monthly 20 Day Moving Average: 63,445 shares Shares Outstanding: 6.12 (millions) Market Capitalization: $267.42 (millions) Beta: 1.01 52 Week High: $54.30 52 Week Low: $1.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.79% 22.99% 12 Week 2.39% -15.75% Year To Date 98.77% 86.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SKOKIE BLVD SUITE 350 - WILMETTE,IL 60091 USA ph: 847-388-0349 fax: - vu@monopartx.com http://www.monopartx.com

• General Corporate Information    Officers Chandler D. Robinson - Chief Executive Officer Christopher M. Starr - Executive Chairman Quan Vu - Chief Financial Officer Raymond W. Anderson - Director Arthur J. Klausner - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61023L207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 6.12 Most Recent Split Date: 8.00 (0.20:1) Beta: 1.01 Market Capitalization: $267.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.99 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 24.00% vs. Previous Quarter: 82.96% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -55.39 12/31/24 - -84.76 ROA 06/30/25 - - 03/31/25 - -51.53 12/31/24 - -75.61 Current Ratio 06/30/25 - - 03/31/25 - 36.91 12/31/24 - 11.48 Quick Ratio 06/30/25 - - 03/31/25 - 36.91 12/31/24 - 11.48 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 8.76 12/31/24 - 9.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©